Citations

Clear

1320 citation(s) found for "Nguyen, Vi".

Proton versus photon adjuvant radiotherapy: a multicenter comparative evaluation of recurrence following spinal chordoma resection
Nguyen, Ryan, Ravindran, Krishnan , Perez‐Vega, Carlos , Dominari, Asmina, Battistin, Umberto , Suárez-Meade, Paola , Kalani, Maziyar A. , Rose, Peter S. , Bydon, Mohamad , Dominari, Asimina , Montaser, Alaa, Perez-Vega, Carlos, Lee, Seung-Jin, Moussalem, Charbel, Ghaith, Abdul Karim , Nguyen, Ryan, El-Hajj, Victor Gabriel , Montaser, Alaa S. , Biase, Gaetano De , Lee, Seung Jin, Moussalem, Charbel K. , Patel, Naresh P. , Clarke, Michelle J. , Abode-Iyamah, Kingsley , Akinduro, Oluwaseun O.

Mayo Clinic

Neurosurgical Focus | May 4, 2024 | Volume: 56 | Issue: 5 | Pages: E9

10.3171/2024.2.focus23927 | PMID 38691864 Get It

OBJECTIVE Chordomas are rare tumors of the skull base and spine believed to arise from the vestiges of the embryonic notochord. These tumors are locally aggressive and frequently recur following resection and adjuvant radiotherapy. Proton therapy has been introduced as a tissue-sparing option because of the higher level of precision that proton-beam techniques offer compared with traditional photon radiotherapy. This study aimed to compare recurrence in patients with chordomas receiving proton versus photon radiotherapy following resection by applying tree-based machine learning models. METHODS The clinical records of all patients treated with resection followed by adjuvant proton or photon radiotherapy for chordoma at Mayo Clinic were reviewed. Patient demographics, type of surgery and radiotherapy, tumor recurrence, and other variables were extracted. Decision tree classifiers were trained and tested to predict long-term recurrence based on unseen data using an 80/20 split. RESULTS Fifty-three patients with a mean ± SD age of 55.2 ± 13.4 years receiving surgery and adjuvant proton or photon therapy to treat chordoma were identified; most patients were male. Gross-total resection was achieved in 54.7% of cases. Proton therapy was the most common adjuvant radiotherapy (84.9%), followed by conventional or external-beam radiation therapy (9.4%) and stereotactic radiosurgery (5.7%). Patients receiving proton therapy exhibited a 40% likelihood of having recurrence, significantly lower than the 88% likelihood observed in those treated with nonproton therapy. This was confirmed on logistic regression analysis adjusted for extent of tumor resection and tumor location, which revealed that proton adjuvant radiotherapy was associated with a decreased risk of recurrence (OR 0.1, 95% CI 0.01–0.71; p = 0.047) compared with photon therapy. The decision tree algorithm predicted recurrence with an accuracy of 90% (95% CI 55.5%–99.8%), with the lowest risk of recurrence observed in patients receiving gross-total resection with adjuvant proton therapy (23%). CONCLUSIONS Following resection, adjuvant proton therapy was associated with a lower risk of chordoma recurrence compared with photon therapy. The described machine learning models were able to predict tumor progression based on the extent of tumor resection and adjuvant radiotherapy modality used.
Association of preprocedural antiplatelet use with decreased thromboembolic complications for intracranial aneurysms undergoing intrasaccular flow disruption
Diestro, Jose Danilo Bengzon , Adeeb, Nimer , Aslan, Assala , McLellan, Rachel , Lay, Sovann V. , Guenego, Adrien , Naamani, Kareem El, Shotar, Eimad, Premat, Kévin , Möhlenbruch, Markus , Kral, Michael , Doron, Omer , Salem, Mohamed M. , Foreman, Paul M. , Vachhani, Jay A. , Shaikh, Hamza , Župančić, Vedran , Mohammed, Marwa A. , İmamoğlu, Çetin , Bayrak, Ahmet , Rabinov, James D. , Ren, Yifan , Michelozzi, Caterina , Elens, Stéphanie , Starke, Robert M. , Ogilvie, Mark , Nguyên, Anh , Jones, Jesse , Brinjikji, Waleed , Nawka, Marie Teresa , Psychogios, Marios, Ulfert, Christian , Pukenas, Bryan , Burkhardt, Jan‐Karl , Essibayi, Muhammed Amir , Spiegel, Gary, Lubicz, Boris , Puri, Ajit S , Pero, Guglielmo , Nossek, Erez , Raz, Eytan , Asadi, Hamed , Siddiqui, Adnan H. , Brook, Allan , Altschul, David , Spears, Julian , Marotta, Thomas R. , Ducruet, Andrew F. , Albuquerque, Felipe C. , Regenhardt, Robert W. , Stapleton, Christopher J. , Kan, Peter , Kalousek, Vladimir , Lylyk, Pedro , Boddu, Srikanth , Knopman, Jared , Tjoumakaris, Stavropoula , Clarençon, Frédéric , Patel, Aman B. , Bayrak, Ahmet , Ibrahim, Mohamed K. , Siddiqui, Adnan H , Diestro, Jose Danilo B , Shotar, Eimad , Nguyen, Anh , Pero, Guglielmo , Kalousek, Vladimir , Altschul, David J , Regenhardt, Robert W , Essibayi, Muhammed Amir , Ulfert, Christian , Lay, Sovann V , Burkhardt, Jan‐Karl , Musmar, Basel , Salim, Hamza , Cancelliere, Nicole M , Algin, Oktay , Ghozy, Sherief , Renieri, Leonardo , Carnevale, Joseph Anthony , Saliou, Guillaume , Mastorakos, Panagiotis , Naamani, Kareem El , Shotar, Eimad , Bernstock, Joshua D. , Chung, Charlotte , Lylyk, Iván , Hafeez, Muhammad Ubaid , Catapano, Joshua S , Waqas, Muhammad , Schirmer, Clemens M. , Piano, Mariangela , Kühn, Anna Luisa , Hassan, Ameer E , Psychogios, Marios‐Nikos , Huynh, Thien , Martinez-Gutierrez, Juan Carlos , Sheth, Sunil A , Tawk, Rabih G. , Panni, Pietro , Killer-Oberpfalzer, Monika , Griessenauer, Christoph J. , Aziz‐Sultan, Mohammad Ali , Jabbour, Pascal , Limbucci, Nicola , Cuellar, Hugo , Mendes Pereira, Vitor , Dmytriw, Adam A.

Mayo Clinic

Journal of Neurosurgery | May 3, 2024 | Volume: 141 | Issue: 4 | Pages: 992-999

10.3171/2024.2.jns232918 | PMID 38701528 Get It

OBJECTIVE This study was conducted to investigate the impact of antiplatelet administration in the periprocedural period on the occurrence of thromboembolic complications (TECs) in patients undergoing treatment using the Woven EndoBridge (WEB) device for intracranial wide-necked bifurcation aneurysms. The primary objective was to assess whether the use of antiplatelets in the pre- and postprocedural phases reduces the likelihood of developing TECs, considering various covariates. METHODS A retrospective multicenter observational study was conducted within the WorldWideWEB Consortium and comprised 38 academic centers with endovascular treatment capabilities. Univariable and multivariable logistic regression analyses were performed to determine the association between antiplatelet use and TECs, adjusting for covariates. Missing predictor data were addressed using multiple imputation. RESULTS The study comprised two cohorts: one addressing general thromboembolic events and consisting of 1412 patients, among whom 103 experienced TECs, and another focusing on symptomatic thromboembolic events and comprising 1395 patients, of whom 50 experienced symptomatic TECs. Preprocedural antiplatelet use was associated with a reduced likelihood of overall TECs (OR 0.32, 95% CI 0.19–0.53, p < 0.001) and symptomatic TECs (OR 0.49, 95% CI 0.25–0.95, p = 0.036), whereas postprocedural antiplatelet use showed no significant association with TECs. The study also revealed additional predictors of TECs, including stent use (overall: OR 4.96, 95% CI 2.38–10.3, p < 0.001; symptomatic: OR 3.24, 95% CI 1.26–8.36, p = 0.015), WEB single-layer sphere (SLS) type (overall: OR 0.18, 95% CI 0.04–0.74, p = 0.017), and posterior circulation aneurysm location (symptomatic: OR 18.43, 95% CI 1.48–230, p = 0.024). CONCLUSIONS The findings of this study suggest that the preprocedural administration of antiplatelets is associated with a reduced likelihood of TECs in patients undergoing treatment with the WEB device for wide-necked bifurcation aneurysms. However, postprocedural antiplatelet use did not show a significant impact on TEC occurrence.
Abstract PO2-12-08: Increased burden of genetic variants in idiopathic cardiomyopathy genes is associated with cancer therapy-related cardiomyopathy
Norton, Nadine , Nguyen, Thien , Reddy, Joseph S. , Harvey, Jinky, Weidner, Morgan, Evans, Lily, Vallow, Laura A., Advani, Pooja , Norton, Nadine , Arnold, Amanda

Mayo Clinic

Cancer Research | May 2, 2024 | Volume: 84 | Issue: 9_Supplement | Pages: PO2-12-08-PO2-12-08

10.1158/1538-7445.sabcs23-po2-12-08 Get It

Abstract Background: Breast cancer (BC) patients are at significant risk of therapy-related cardiotoxicity, but prediction of which patients will experience cardiotoxicity and the severity of the outcome are lacking. We hypothesized that germline genetic variants are potential risk factors for cancer treatment-related cardiomyopathy (CTRC) and in this study, we focused on rare non-synonymous variants within 57 genes deemed causative of familial and sporadic forms of idiopathic cardiomyopathies. Methods: We developed a clinical database and biorepository for patients receiving any potentially cardiotoxic cancer therapy at Mayo Clinic Florida. Enrollment is ongoing and includes consent to access external records. Patient data is extracted from records at baseline, completion of treatment and then once per year. The clinical database includes the following datasets: demographics, pathology, chemotherapy, radiation, echocardiography, cardiac MRI, PET/CT scan, blood pressure, BMI, labs, treatment complications. Treatment complications includes pre-existing conditions (smoking, alcohol and drug use history, hypertension, diabetes, coronary artery disease, hyperlipidemia, prior stroke or myocardial infarction, peripheral vascular disease, renal failure); cardiac medications at baseline; cardiac side-effects; time to cardiotoxicity; cardiotoxicity interventions and outcomes. Exome sequencing was performed by the Mayo Clinic NGS core on the first 86 patients in the registry, average of ~120x read depth following Illumina’s standard protocol for the NovaSeq 6000 and S4 flow cell. Genomic variants were extracted for 57 genes known to be causative of dilated, hypertrophic and arrhythmogenic right ventricular cardiomyopathies and channelopathies. Putative risk variants in known cardiomyopathy genes were defined as non-synonymous variants with a frequency of &lt; 0.0004 in the GnomAD database. We compared the number of patients with putative risk variants in those groups with and without CTRC. Results: 84/86 patients had BC diagnosis. Key characteristics are described in the table below. 60/86 (70%) patients had at least one putative risk variant in one of 31 genes (there were no risk variants identified in 27/57 genes). The average number of putative risk variants per patient within the CTRC group was higher than that observed in patients without CTRC (2.06 vs 1.62). Post-hoc analysis suggested this difference is largely from patients with &gt;2 risk variants in the group who experienced CTRC (N=7/17, 41%) compared to those who did not (N=14/69, 20%), p=0.023. Conclusions: Rare missense variants in the causative genes of idiopathic cardiomyopathies are potential risk factors for CTRC and risk may be increased in patients with a higher burden of variants. Analysis of the genetic data from patients that continue to be accrued in this study, including effects of additional clinical risk factors will be undertaken to improve prediction of cardiotoxicity. Table 1 Distribution of putative cardiomyopathy genetic variants in 86 cancer patients with and without treatment-related cardiomyopathy, separated by treatment regimen Citation Format: Nadine Norton, Thien Nguyen, Joseph Reddy, Jinky Harvey, Morgan Weidner, Amanda Arnold, Lily Evans, Laura Vallow, Pooja Advani. Increased burden of genetic variants in idiopathic cardiomyopathy genes is associated with cancer therapy-related cardiomyopathy [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO2-12-08.
Extracorporeal Membrane Oxygenation (ECMO) and Continuous Renal Replacement Therapy (CRRT): A Descriptive Review of Observations
Truong, Hoang Quan , Nikravangolsefid, N., Nikravangolsefid, Nasrin , Subramanyam, S., Nguyen, C., Tekin, Aysun , Suppadungsuk, Supawadee , Kashani, Kianoush

Mayo Clinic

C41. PUMP YOU UP - ECMO AND CARDIAC DEVICE OPTIMIZATION | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A5523-A5523

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a5523 Get It

"By the Skin of Our Teeth": Managing Resource Scarcity During the COVID-19 Pandemic
Ennis, Jon, Nguyen, N.V. , DeMartino, Erin S. , Ennis, J., Riggan, Kirsten A.

Mayo Clinic

B102. OPTIMIZING ICU PROCESSES AND CARE: ADOPTING BEST PRACTICES | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A4786-A4786

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a4786 Get It

How Are Professional Medical Societies Addressing Mass Incarceration and Carceral Health Through Official Society Policy Statements and Guidance?
Nguyen, N.V. , Sergew, Amen, DeMartino, Erin S. , Akgün, Kathleen M. , Griffith, Matthew F.

Mayo Clinic

C103. DISPARITIES AND SOCIAL DETERMINANTS OF HEALTH IN PULMONARY, CRITICAL CARE, AND SLEEP MEDICINE | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A6729-A6729

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a6729 Get It

Omission of Axillary Dissection Following Nodal Downstaging With Neoadjuvant Chemotherapy
Montagna, Giacomo , Mrdutt, Mary M., Hlavin, Callie , Diego, Emilia J. , Wong, Stephanie M. , Barrio, Andrea V. , Bruele, Astrid Botty van den , Cabıoğlu, Neslihan , Sevilimedu, Varadan , Hwang, E. Shelley, Ingham, Abigail, Papassotiropoulos, Bärbel , Nguyen-Sträuli, Bich Doan , Kurzeder, Christian , Aybar, Danilo Díaz, Vorburger, Denise , Matlac, Dieter Michael, Fitzal, Florian , Meani, Francesco , Fick, Franziska, Sagasser, Jacqueline, Heil, Jörg, Dedes, Konstantin J. , Romics, László , Banys‐Paluchowski, Maggie , Müslümanoğlu, Mahmut , Pérez, María del Rosario Cueva, Díaz, Marcelo Chávez , Heidinger, Martin , Fehr, Mathias K. , Tükenmez, Mustafa , Maggi, Nadia , Ditsch, Nina , Zarhi, Sebastián Solé, Küemmel, Sherko , Bruz̆as, S., Lascio, Simona Di , Parissenti, Tamara K., Güth, Uwe , Ovalle, Valentina , Tausch, Christoph, Kuerer, Henry M. , Caudle, Abigail S. , Boileau, Jean-François , Kühn, Thorsten, Morrow, Monica , Weber, William P. , Hoskin, Tanya L. , Heidinger, Martin , Weber, Walter P , Wong, Stephanie M , Mrdutt, Mary M , Sun, Susie X. , Rosenberger, Laura H. , Matlac, Dieter Michael , Ostapenko, Edvin , Riedel, Fabian , Heil, Jörg, Karanlık, Hasan , Reinisch, Mattea , Rocco, Nicola , Gentilini, Oreste D , Paulinelli, Régis Resende , Boughey, Judy C.

Mayo Clinic

JAMA Oncology | April 25, 2024 | Volume: 10 | Issue: 6 | Pages: 793

10.1001/jamaoncol.2024.0578 | PMID 38662396 Get It

ImportanceData on oncological outcomes after omission of axillary lymph node dissection (ALND) in patients with breast cancer that downstages from node positive to negative with neoadjuvant chemotherapy are sparse. Additionally, the best axillary surgical staging technique in this scenario is unknown.ObjectiveTo investigate oncological outcomes after sentinel lymph node biopsy (SLNB) with dual-tracer mapping or targeted axillary dissection (TAD), which combines SLNB with localization and retrieval of the clipped lymph node.Design, Setting, and ParticipantsIn this multicenter retrospective cohort study that was conducted at 25 centers in 11 countries, 1144 patients with consecutive stage II to III biopsy-proven node-positive breast cancer were included between April 2013 and December 2020. The cumulative incidence rates of axillary, locoregional, and any invasive (locoregional or distant) recurrence were determined by competing risk analysis.ExposureOmission of ALND after SLNB or TAD.Main Outcomes and MeasuresThe primary end points were the 3-year and 5-year rates of any axillary recurrence. Secondary end points included locoregional recurrence, any invasive (locoregional and distant) recurrence, and the number of lymph nodes removed.ResultsA total of 1144 patients (median [IQR] age, 50 [41-59] years; 78 [6.8%] Asian, 105 [9.2%] Black, 102 [8.9%] Hispanic, and 816 [71.0%] White individuals; 666 SLNB [58.2%] and 478 TAD [41.8%]) were included. A total of 1060 patients (93%) had N1 disease, 619 (54%) had ERBB2 (formerly HER2)–positive illness, and 758 (66%) had a breast pathologic complete response. TAD patients were more likely to receive nodal radiation therapy (85% vs 78%; P = .01). The clipped node was successfully retrieved in 97% of TAD cases and 86% of SLNB cases (without localization). The mean (SD) number of sentinel lymph nodes retrieved was 3 (2) vs 4 (2) (P &amp;lt; .001), and the mean (SD) number of total lymph nodes removed was 3.95 (1.97) vs 4.44 (2.04) (P &amp;lt; .001) in the TAD and SLNB groups, respectively. The 5-year rates of any axillary, locoregional, and any invasive recurrence in the entire cohort were 1.0% (95% CI, 0.49%-2.0%), 2.7% (95% CI, 1.6%-4.1%), and 10% (95% CI, 8.3%-13%), respectively. The 3-year cumulative incidence of axillary recurrence did not differ between TAD and SLNB (0.5% vs 0.8%; P = .55).Conclusions and RelevanceThe results of this cohort study showed that axillary recurrence was rare in this setting and was not significantly lower after TAD vs SLNB. These results support omission of ALND in this population.
Reply: Prospective Multicenter Evaluation of Pain Before and After Removal of Nonobstructing Renal Calculi: A CoRE Initiative
Bhojani, Naeem , Wollin, Daniel , Tayeb, Marawan M. El , Scotland, Kymora B. , Knoedler, John, Stern, Karen , Nguyen, David‐Dan , Rivera, Marcelino , Borofsky, Michael S. , Canvasser, Noah, Bechis, Seth K. , Hsi, Ryan S. , Stern, Karen L , Hsi, Ryan

Mayo Clinic

Journal of Urology | April 25, 2024 | Volume: 212 | Issue: 1 | Pages: 232-232

10.1097/ju.0000000000003956 | PMID 38661068 Get It

Amino Terminal Acetylation of HOXB13 Regulates the DNA Damage Response in Prostate Cancer
Nguyen, Duy T. , Mahajan, Urvashi , Angappulige, Duminduni H. , Doshi, Aashna, Mahajan, Nupam P. , Mahajan, Kiran

Mayo Clinic

Cancers | April 23, 2024 | Volume: 16 | Issue: 9 | Pages: 1622

10.3390/cancers16091622 | PMID 38730575 Get It

Advanced localized prostate cancers (PC) recur despite chemotherapy, radiotherapy and/or androgen deprivation therapy. We recently reported HOXB13 lysine (K)13 acetylation as a gain-of-function modification that regulates interaction with the SWI/SNF chromatin remodeling complex and is critical for anti-androgen resistance. However, whether acetylated HOXB13 promotes PC cell survival following treatment with genotoxic agents is not known. Herein, we show that K13-acetylated HOXB13 is induced rapidly in PC cells in response to DNA damage induced by irradiation (IR). It colocalizes with the histone variant γH2AX at sites of double strand breaks (DSBs). Treatment of PCs with the Androgen Receptor (AR) antagonist Enzalutamide (ENZ) did not suppress DNA-damage-induced HOXB13 acetylation. In contrast, HOXB13 depletion or loss of acetylation overcame resistance of PC cells to ENZ and synergized with IR. HOXB13K13A mutants show diminished replication fork progression, impaired G2/M arrest with significant cell death following DNA damage. Mechanistically, we found that amino terminus regulates HOXB13 nuclear puncta formation that is essential for proper DNA damage response. Therefore, targeting HOXB13 acetylation with CBP/p300 inhibitors in combination with DNA damaging therapy may be an effective strategy to overcome anti-androgen resistance of PCs.